-$0.42 Earnings Per Share Expected for Myovant Sciences Ltd (MYOV) This Quarter
Analysts predict that Myovant Sciences Ltd (NYSE:MYOV) will post ($0.42) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Myovant Sciences’ earnings. The lowest EPS estimate is ($0.45) and the highest is ($0.39). Myovant Sciences reported earnings per share of ($0.15) in the same quarter last year, which suggests a negative year-over-year growth rate of 180%. The business is expected to report its next quarterly earnings results on Monday, January 1st.
According to Zacks, analysts expect that Myovant Sciences will report full-year earnings of ($1.74) per share for the current financial year, with EPS estimates ranging from ($1.79) to ($1.68). For the next fiscal year, analysts anticipate that the company will post earnings of ($1.95) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that follow Myovant Sciences.
Several analysts have recently issued reports on MYOV shares. Zacks Investment Research cut Myovant Sciences from a “hold” rating to a “sell” rating in a report on Friday, November 17th. JMP Securities reaffirmed an “outperform” rating and set a $25.00 price objective (up from $23.00) on shares of Myovant Sciences in a report on Wednesday, October 4th. Robert W. Baird reaffirmed a “buy” rating and set a $20.00 price objective on shares of Myovant Sciences in a report on Friday, November 10th. Finally, Cowen reaffirmed a “buy” rating on shares of Myovant Sciences in a report on Tuesday, October 3rd. One analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $22.50.
Myovant Sciences (NYSE MYOV) traded up $0.07 during midday trading on Wednesday, reaching $12.43. The company had a trading volume of 85,800 shares, compared to its average volume of 55,105. Myovant Sciences has a one year low of $9.92 and a one year high of $18.85. The stock has a market cap of $753.83, a PE ratio of -8.82 and a beta of -2.42.
Several institutional investors and hedge funds have recently modified their holdings of MYOV. Goldman Sachs Group Inc. purchased a new stake in shares of Myovant Sciences during the 2nd quarter worth approximately $174,000. Swiss National Bank bought a new position in shares of Myovant Sciences during the 2nd quarter valued at approximately $294,000. OxFORD Asset Management LLP increased its position in shares of Myovant Sciences by 15.4% during the 2nd quarter. OxFORD Asset Management LLP now owns 29,745 shares of the company’s stock valued at $348,000 after purchasing an additional 3,971 shares during the last quarter. Susquehanna International Group LLP bought a new position in shares of Myovant Sciences during the 2nd quarter valued at approximately $648,000. Finally, Point72 Asset Management L.P. bought a new position in shares of Myovant Sciences during the 3rd quarter valued at approximately $1,255,000. 79.21% of the stock is currently owned by institutional investors and hedge funds.
About Myovant Sciences
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with Analyst Ratings Network's FREE daily email newsletter.